< Back

ABSTRACT




Perspectives on the use of tyrosine kinase inhibitors in thyroid cancer

doi: 10.24875/j.gamo.19000229

Full Article in PDF (Spanish)


VOLUME 19 - NUMBER 1 / January-March (Review Article / Artículo de Revisión)


Miguel Quintana-Quintana, Department of Medical Oncology, Hospital General Naval de Alta Especialidad, Coyoacán, Ciudad de México, Mexico
David Orta-Cortes, Department of Oncology, Centro Médico Naval, Secretaría de Marina, Mexico City, Mexico
Miguel A. Tletlepantzin-Apartado, Department of Oncology, Centro Médico Naval, Secretaría de Marina, Mexico City, Mexico
José A. Toriz-Hernández, Department of Oncology, Centro Médico Naval, Secretaría de Marina, Mexico City, Mexico
Viridiana Méndez-Calderillo, Department of Oncology, Centro Médico Naval, Secretaría de Marina, Mexico City, Mexico
Sandra R. Paredes-Fernández, Department of Nuclear Medicine, Centro Médico Naval, Secretaría de Marina, Mexico City, Mexico
Tania P. Álvarez-Domínguez, Department of Pathology, Centro Médico Naval, Secretaría de Marina, Mexico City, Mexico
Josué Mora-Pérez, Department of Oncology, Centro Médico Naval, Secretaría de Marina, Mexico City, Mexico



Introduction: Thyroid cancer has generally a good prognosis after surgical and/or radioactive iodine (RAI) treatment; however, these tumors that persist or that are not candidate to these treatments have a worse prognosis, which makes the use of tyrosine kinase inhibitors (TKIs) a good management alternative, since it has demonstrated progression-free survival (PFS) and response rate benefits, and it is, therefore, important to describe new markers and future therapies for this type of tumors. Materials and methods: The purpose of this review is to describe the current state of the treatment of advanced or relapsing thyroid cancer that is not susceptible to management with surgery or RAI, the benefits, and limitations of the use of TKIs, as well as an analysis of this tumor’s molecular biology and its clinical repercussion. Results: The use of sorafenib and lenvatinib in differentiated thyroid carcinoma that is refractory to RAI, and cabozantinib and vandetanib for advanced medullary carcinomas, has demonstrated benefit in this type of patients, with an impact on PFS, response rates, and disease control. There are ongoing studies with immunotherapy, and we will be alert for their results. Conclusion: The treatment with TKI in metastatic thyroid cancer, has shown benefit, the determination of mutations and markers will determine which is the best TKI for the different subtypes of thyroid cancer.


Keywords: Thyroid cancer. Tyrosine kinase inhibitors. Treatment.